Market capitalization | CHF142.40m |
Enterprise Value | CHF291.90m |
P/E (TTM) P/E ratio | 6.53 |
EV/FCF (TTM) EV/FCF | 153.63 |
EV/Sales (TTM) EV/Sales | 294.85 |
P/S ratio (TTM) P/S ratio | 143.84 |
P/B ratio (TTM) P/B ratio | 0.52 |
Revenue growth (TTM) Revenue growth | -1.32% |
Revenue (TTM) Revenue | CHF990.00k |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Xlife Sciences:
1 Analyst has issued a forecast Xlife Sciences:
Jun '24 |
+/-
%
|
||
Revenue | 0.99 0.99 |
1%
1%
|
|
Gross Profit | -17 -17 |
9%
9%
|
|
EBITDA | -2.67 -2.67 |
53%
53%
|
EBIT (Operating Income) EBIT | -19 -19 |
14%
14%
|
Net Profit | 21 21 |
32%
32%
|
In millions CHF.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Xlife Sciences AG focuses on the value development of performance promising technologies in life sciences. The company is headquartered in Zurich, Switzerland.
Head office | Switzerland |
CEO | Oliver Baumann |
Website | www.xlifesciences.ch |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.